. "V\u00FDchodiska: Kolorekt\u00E1ln\u00ED karcinom je v \u010Cesk\u00E9 republice druhou nej\u010Dast\u011Bj\u0161\u00ED malignitou. Z\u00E1kladn\u00ED l\u00E9\u010Debnou metodou diseminovan\u00E9ho onemocn\u011Bn\u00ED je syst\u00E9mov\u00E1 paliativn\u00ED chemoterapie zalo\u017Een\u00E1 na aplikaci 5-fluorouracilu s leukovorinem a irinotekanem, event. oxaliplatinou. Kombinac\u00ED s c\u00EDlenou biologickou l\u00E9\u010Dbou monoklon\u00E1ln\u00EDmi protil\u00E1tkami proti vaskul\u00E1rn\u00EDmu endotelov\u00E9mu r\u016Fstov\u00E9mu faktoru (VEGF) a receptoru pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (EGFR) lze p\u0159i v\u010Dasn\u00E9 indikaci doc\u00EDlit v\u00FDrazn\u00FDch a dlouhodob\u00FDch klinick\u00FDch odpov\u011Bd\u00ED. P\u0159\u00EDpad: Kazuistika demonstruje pr\u016Fb\u011Bh onemocn\u011Bn\u00ED 34let\u00E9ho pacienta s adenokarcinomem sigmatu (stadium Dukes C), kter\u00FD byl po prim\u00E1rn\u00ED operaci v roce 2002 a po zaji\u0161t\u011Bn\u00ED adjuvantn\u00ED chemoterapi\u00ED re\u017Eimem FOLFIRI (12 s\u00E9ri\u00ED) po dobu 5 let bez zn\u00E1mek n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED. V listopadu roku 2007 do\u0161lo k solit\u00E1rn\u00EDmu relapsu v retroperitoneu, n\u00E1sledovala neradik\u00E1ln\u00ED operace (pozitivn\u00ED okraje), adjuvantn\u00ED chemoterapie re\u017Eimem FOLFOX 4 (12 s\u00E9ri\u00ED) a c\u00EDlen\u00E1 radioterapie na oblast retroperitonea (do kv\u011Btna roku 2008). Vzhledem k \u010Dasn\u00E9mu relapsu onemocn\u011Bn\u00ED v \u010Dervnu roku 2008 (podkl\u00ED\u010Dek, hrudn\u00ED st\u011Bna, retroperitoneum) byla zah\u00E1jena I. linie paliativn\u00ED chemoterapie re\u017Eimem XELIRI + bevacizumab s efektem parci\u00E1ln\u00ED remise (PR) po 3 m\u011Bs\u00EDc\u00EDch a dosa\u017Een\u00ED kompletn\u00ED remise onemocn\u011Bn\u00ED (CR) po 6 m\u011Bs\u00EDc\u00EDch l\u00E9\u010Dby. V l\u00E9\u010Db\u011B bevacizumabem v monoterapii pokra\u010Dov\u00E1no dal\u0161\u00EDch 8 m\u011Bs\u00EDc\u016F do b\u0159ezna roku 2010, kdy do\u0161lo k progresi na plic\u00EDch. Po vylou\u010Den\u00ED mutace genu KRAS byla zah\u00E1jena II. linie paliativn\u00ED bio-chemoterapie re\u017Eimem irinotekan + cetuximab, kter\u00E1 vyk\u00E1zala rovn\u011B\u017E velmi dobr\u00FD efekt \u2013 dosa\u017Een\u00ED t\u00E9m\u011B\u0159 kompletn\u00ED remise po necel\u00FDch 6 m\u011Bs\u00EDc\u00EDch l\u00E9\u010Dby a udr\u017Een\u00ED t\u00E9to remise po dal\u0161\u00EDch 6 m\u011Bs\u00EDc\u016F p\u0159i monoterapii cetuximabem. To v\u0161e p\u0159i minim\u00E1ln\u00ED toxicit\u011B l\u00E9\u010Dby a velmi dobr\u00E9 kvalit\u011B \u017Eivota prezentovan\u00E9ho pacienta."@cs . "6" . . . "The role of chemotherapy and targeted antiVEGFand antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and Intensive response"@en . . . . "http://www.linkos.cz/files/klinicka-onkologie/167/3904.pdf" . "2"^^ . "V\u00FDchodiska: Kolorekt\u00E1ln\u00ED karcinom je v \u010Cesk\u00E9 republice druhou nej\u010Dast\u011Bj\u0161\u00ED malignitou. Z\u00E1kladn\u00ED l\u00E9\u010Debnou metodou diseminovan\u00E9ho onemocn\u011Bn\u00ED je syst\u00E9mov\u00E1 paliativn\u00ED chemoterapie zalo\u017Een\u00E1 na aplikaci 5-fluorouracilu s leukovorinem a irinotekanem, event. oxaliplatinou. Kombinac\u00ED s c\u00EDlenou biologickou l\u00E9\u010Dbou monoklon\u00E1ln\u00EDmi protil\u00E1tkami proti vaskul\u00E1rn\u00EDmu endotelov\u00E9mu r\u016Fstov\u00E9mu faktoru (VEGF) a receptoru pro epiderm\u00E1ln\u00ED r\u016Fstov\u00FD faktor (EGFR) lze p\u0159i v\u010Dasn\u00E9 indikaci doc\u00EDlit v\u00FDrazn\u00FDch a dlouhodob\u00FDch klinick\u00FDch odpov\u011Bd\u00ED. P\u0159\u00EDpad: Kazuistika demonstruje pr\u016Fb\u011Bh onemocn\u011Bn\u00ED 34let\u00E9ho pacienta s adenokarcinomem sigmatu (stadium Dukes C), kter\u00FD byl po prim\u00E1rn\u00ED operaci v roce 2002 a po zaji\u0161t\u011Bn\u00ED adjuvantn\u00ED chemoterapi\u00ED re\u017Eimem FOLFIRI (12 s\u00E9ri\u00ED) po dobu 5 let bez zn\u00E1mek n\u00E1dorov\u00E9ho onemocn\u011Bn\u00ED. V listopadu roku 2007 do\u0161lo k solit\u00E1rn\u00EDmu relapsu v retroperitoneu, n\u00E1sledovala neradik\u00E1ln\u00ED operace (pozitivn\u00ED okraje), adjuvantn\u00ED chemoterapie re\u017Eimem FOLFOX 4 (12 s\u00E9ri\u00ED) a c\u00EDlen\u00E1 radioterapie na oblast retroperitonea (do kv\u011Btna roku 2008). Vzhledem k \u010Dasn\u00E9mu relapsu onemocn\u011Bn\u00ED v \u010Dervnu roku 2008 (podkl\u00ED\u010Dek, hrudn\u00ED st\u011Bna, retroperitoneum) byla zah\u00E1jena I. linie paliativn\u00ED chemoterapie re\u017Eimem XELIRI + bevacizumab s efektem parci\u00E1ln\u00ED remise (PR) po 3 m\u011Bs\u00EDc\u00EDch a dosa\u017Een\u00ED kompletn\u00ED remise onemocn\u011Bn\u00ED (CR) po 6 m\u011Bs\u00EDc\u00EDch l\u00E9\u010Dby. V l\u00E9\u010Db\u011B bevacizumabem v monoterapii pokra\u010Dov\u00E1no dal\u0161\u00EDch 8 m\u011Bs\u00EDc\u016F do b\u0159ezna roku 2010, kdy do\u0161lo k progresi na plic\u00EDch. Po vylou\u010Den\u00ED mutace genu KRAS byla zah\u00E1jena II. linie paliativn\u00ED bio-chemoterapie re\u017Eimem irinotekan + cetuximab, kter\u00E1 vyk\u00E1zala rovn\u011B\u017E velmi dobr\u00FD efekt \u2013 dosa\u017Een\u00ED t\u00E9m\u011B\u0159 kompletn\u00ED remise po necel\u00FDch 6 m\u011Bs\u00EDc\u00EDch l\u00E9\u010Dby a udr\u017Een\u00ED t\u00E9to remise po dal\u0161\u00EDch 6 m\u011Bs\u00EDc\u016F p\u0159i monoterapii cetuximabem. To v\u0161e p\u0159i minim\u00E1ln\u00ED toxicit\u011B l\u00E9\u010Dby a velmi dobr\u00E9 kvalit\u011B \u017Eivota prezentovan\u00E9ho pacienta." . "RIV/00209805:_____/11:#0000204" . "[11BFA3F50455]" . "Pou\u017Eit\u00ED chemoterapie v kombinaci s c\u00EDlenou biologickou l\u00E9\u010Dbou u diseminovan\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu: kazuistika dlouhodob\u00E9 a v\u00FDrazn\u00E9 klinick\u00E9 odpov\u011Bdi" . "Pou\u017Eit\u00ED chemoterapie v kombinaci s c\u00EDlenou biologickou l\u00E9\u010Dbou u diseminovan\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu: kazuistika dlouhodob\u00E9 a v\u00FDrazn\u00E9 klinick\u00E9 odpov\u011Bdi"@cs . "2"^^ . "CZ - \u010Cesk\u00E1 republika" . . . . "Pou\u017Eit\u00ED chemoterapie v kombinaci s c\u00EDlenou biologickou l\u00E9\u010Dbou u diseminovan\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu: kazuistika dlouhodob\u00E9 a v\u00FDrazn\u00E9 klinick\u00E9 odpov\u011Bdi" . "RIV/00209805:_____/11:#0000204!RIV12-MZ0-00209805" . "0862-495X" . "222094" . . "24" . . "N\u011Bme\u010Dek, Radim" . "The role of chemotherapy and targeted antiVEGFand antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and Intensive response"@en . "Vyzula, Rostislav" . . . . "colorectal cancer; bevacizumab; cetuximab"@en . "5"^^ . "I" . . "Klinick\u00E1 onkologie" . "Pou\u017Eit\u00ED chemoterapie v kombinaci s c\u00EDlenou biologickou l\u00E9\u010Dbou u diseminovan\u00E9ho kolorekt\u00E1ln\u00EDho karcinomu: kazuistika dlouhodob\u00E9 a v\u00FDrazn\u00E9 klinick\u00E9 odpov\u011Bdi"@cs . "Backgrounds: Colorectal cancer (CRC) is the second most frequent malignancy in the Czech Republic. Treatment of a metastatic disease is based on application of palliative chemotherapy (fluorouracil, leucovorin, irinotecan, oxaliplatin). When combined with targeted agents against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), it can result in significant and long-term response. Case: We present a case of a 34-years old man with adenocarcinoma of sigmoid colon (Dukes C) with 5 years disease-free survival (DFS) after primary surgery (in 2002) and adjuvant chemotherapy with FOLFIRI (12 cycles). A solitary relapse in retroperitoneal lymph nodes in November 2007 was treated with retroperiotoneal dissection followed by adjuvant chemotherapy with FOLFOX 4 (12 cycles) and targeted radiotherapy of retroperitoneal area (completed in May 2008). An early relapse occurred one month later (June 2008 \u2013 infraclavicular area, thoracic wall and retroperitoneal lymph nodes), patient underwent first line palliative chemotherapy with XELIRI + bevacizumab leading to partial remission (PR) after 3 months and complete remission (CR) after 6 months of treatment. Bevacizumab monotherapy was continued for the next 8 months up to March 2010, when a progression in the lung occurred. After wild-type status was confirmed, KRAS treatment was changed to the second line combination of irinotecan and cetuximab that resulted in nearly complete remission after 6 months and preservation of this remission after the next 6 months of cetuximab monotherapy. All treatments were well tolerated with good quality of life."@en . .